Aethlon Medical to Announce Fiscal Year-End Results and Host Call on June 27, 2024

Aethlon Medical, Inc., a medical therapeutic company listed on Nasdaq under the ticker AEMD, is set to release its financial results for the fiscal year ending March 31, 2024. These results will be announced at 4:15 p.m. ET on Thursday, June 27, 2024. Following the release, the management team has scheduled a conference call at 4:30 p.m. ET to discuss the financial outcomes and recent corporate developments. This call will also include a question and answer session after the formal remarks by the management.

Participants interested in joining the conference call can register online to receive their dial-in number upon registration. For those without internet access or who are unable to pre-register, there are alternative dial-in options available. The toll-free number for participants is 1-844-836-8741, and the international dial-in number is 1-412-317-5442. Callers are advised to request the Aethlon Medical, Inc. conference call upon dialing in.

For those unable to join the live conference, a replay will be accessible approximately an hour after the conclusion of the call. The replay will be available until July 27, 2024, and can be accessed through Aethlon Medical's website or by dialing 1-877-344-7529 for domestic calls, 1-412-317-0088 for international calls, or 1-855-669-9658 for calls from Canada, using the replay conference ID number 6876352.

Aethlon Medical is known for developing the Hemopurifier, an innovative immunotherapeutic device currently in the clinical stage. The Hemopurifier is designed to address cancer and severe viral infections, with additional applications in organ transplantation. The device has shown efficacy in human studies by removing life-threatening viruses and has demonstrated the removal of harmful exosomes from biological fluids in pre-clinical studies. These exosomes are known to contribute to immune suppression and metastasis in cancer, as well as the severity of life-threatening infectious diseases.

The Hemopurifier has received the U.S. Food and Drug Administration (FDA) Breakthrough Device designation for the treatment of patients with advanced or metastatic cancer who do not respond to or cannot tolerate standard therapies. This designation also applies to cancer types where exosomes contribute to disease progression. Additionally, the Hemopurifier holds another FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application for treating life-threatening viruses that cannot be managed with approved therapies.

Aethlon Medical continues to focus on leveraging its proprietary lectin-based technology to develop therapies that address critical health challenges. This commitment is reflected in their ongoing research and the promising capabilities of the Hemopurifier.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!